Influence of simvastatin on immunological parameters in patients with a metabolic syndrome in a combination to auricules fibrillation
Abstract
60 men with metabolic syndrome in combination with paroxizmal atrial fibrillation were investigated to estimate the influence of simvastatin (simvastol) on the parameters of matrix metalloproteinase-9 and its antagonist – tissue inhibitor of matrix metalloproteinase-1. In all patients the serum level of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1was studied by immunoassay method. The significant decrease of matrix metalloproteinase-9 activity (P=0,043) and increase of the tissue inhibitor of matrix metalloproteinase-1 activity (P=0,018) after simvastol therapy were revealed. Thus, the addition of simvastatin (simvastol) to usual therapy in patients with metabolic syndrome in combination with paroxizmal atrial fibrillation is useful with the pathogenetic position.
About the Authors
V. A. Akhmedov
Omsk State Medical Academy
Россия
Россия
Vadim Adil'evich Akhmedov, MD, professor of the Faculty Therapy Department
Omsk
V. T. Dolgikh
Omsk State Medical Academy
Россия
Россия
Vladimir Terentevich Dolgikh MD, professor The Chief of the Department of Pathofiziology
Omsk
D. V. Naumov
Omsk Railway hospital
Россия
Россия
Dmitriy Valerievich Naumov, k.m.n. The cardiologist of the cardiology unit
V. E. Dvornikov
Omsk Railway hospital
Россия
Россия
Vadim Erievich Dvornikov, k.m.n. The chief of the cardiology unit
References
1. Metalloproteinase activity at the patients with metabolic syndrome and atrial fibrillation /V.A. Akhmedov [et al.] // Vestnik NGU, Seria Biologia, Klinicheskaya medicina. – 2010. –Vol.8, № 4. –P. 113-118.
2. Hezheva F.М. The serum markers of fibrosis at the patients with arterial hypertension / F.М. Hezheva, N.А. Мazur // Kardiologia. – 2006. - №3. – Р. 64-67.
3. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity / F. Cipollone [et al.]// Circulation. – 2004. – Vol. 109., № 12 – Р. 1482-1488.
4. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability / J.L.Johnson //Expert. Rev. Cardiovasc. Ther. – 2007. – Vol. 5, № 2. – Р. 265-282.
5. Luan Z. Statins inhibit secretion of metalloproteinases- 1, -2, -3, and -9 from vascular smooth muscle cells and macrophages / Z. Luan, A.J. Chase, A.C. Newby // Arterioscler. Thromb. Vasc. Biol. – 2003, - Vol. 23. – Р. 769-775.
6. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels / T. Ohtsuka [et al.] // Am. J. Cardiol. – 2003. – Vol.91., № 8 – Р. 1024-1027.
7. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery / Pasterkamp G. [et al.] // Atherosclerosis. – 2000. –Vol. 150. – Р. 245–253.
8. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin / K.E. Porter [et al.]// Cardiovasc. Res. – 2004. - № 64. – Р. 507-515.
Review
For citations:
Akhmedov V.A., Dolgikh V.T., Naumov D.V., Dvornikov V.E. Influence of simvastatin on immunological parameters in patients with a metabolic syndrome in a combination to auricules fibrillation. Yakut Medical Journal. 2011;(3):24-26.
Views:
60
JATS XML
Email this article 